NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator
Email: TACommA@nice.org.uk Fax: +44 (0)207 061 9721
Post: NICE, 10 Spring Gardens, London, SW1A 2BU

I confirm that:

- I agree with the content of the statement submitted by **NCRI Breast Cancer CSG/RCP/RCR/ACP/JCCO** and consequently I will not be submitting a personal statement.

Name: Dr Gianfilippo Bertelli

Signed: [redacted]

Date: 10th February 2014